|
Parameters on admission
|
|
Age (years)
|
65.5 (IQR 55.5–75.1)
|
67.4 (IQR 62.4–75.9)
|
0.105
|
|
Male gender
|
75% (n = 126)
|
87% (n = 41)
|
0.075
|
|
BMI (kg/m2)
|
29 (IQR 25.5–32)
|
30 (IQR 26–34)
|
0.499
|
|
SAPS
|
41 (IQR 32–48)
|
51 (IQR 44–59)
|
< 0.001
|
|
Lymphcytes/nl
|
0.83 (IQR 0.56–1.22)
|
0.77 (IQR 0.38–1.06)
|
0.112
|
|
Neutrophils/nl
|
7.94 (IQR 5.51–11.13)
|
8.14 (IQR 5.55–11.94)
|
0.781
|
|
IL-6 (ng/l)
|
110 (IQR 34.3–315.4)
|
91.65 (IQR 58.3–215)
|
0.868
|
|
CRP (mg/l)
|
142.3 (IQR 68.9–234.3)
|
160.8 (IQR 108.6–270.9)
|
0.167
|
|
PCT (µg/l)
|
0.38 (IQR 0.15–1.49)
|
0.71 (IQR 0.22–2)
|
0.169
|
|
Corticosteroids on admission
|
8% (n = 10)
|
21% (n = 24)
|
< 0.001
|
|
Admission from external ICU
|
42% (n = 71)
|
21% (n = 24)
|
0.283
|
|
ICU treatment parameters
|
|
Number of microbiological samples for Aspergillus spp.
|
3 (IQR 0–7)
|
7 (IQR 5–11)
|
0.000
|
|
Length of ICU stay before onset of CAPA (days)
|
Not applicable
|
8 (IQR 4–14)
|
Not applicable
|
|
Dexamethasone therapy
|
76.2% (n = 128)
|
87.2% (n = 41)
|
0.103
|
|
Cortisol cumulative dose (mg)
|
1.470 (390–2.670)
|
900 (200–2.200)
|
0.154
|
|
Corticosteroid treatment (days)
|
7 (IQR 2–12)
|
6 (IQR 2–10)
|
0.298
|
|
Invasive ventilation (days)
|
12 (IQR 1–32)
|
23 (IQR 16–38)
|
< 0.001
|
|
Days without mechanical ventilation
|
1 (IQR 0–6)
|
1 (IQR 0–5)
|
0.171
|
|
Comorbidities
|
|
Charlson Comorbidity Index
|
5 (IQR 3–7)
|
6 (IQR 5–8)
|
0.015
|
|
Peptic ulcer
|
2% (n = 4)
|
4% (n = 2)
|
0.490
|
|
Rheumatoid disease
|
4% (n = 7)
|
4% (n = 2)
|
0.979
|
|
Heart disease
|
24% (n = 41)
|
15% (n = 7)
|
0.166
|
|
Vascular disease
|
15% (n = 25)
|
17% (n = 8)
|
0.719
|
|
Diabetes
|
31% (52)
|
32% (n = 15)
|
0.900
|
|
Liver disease
|
20% (n = 33)
|
23% (n = 11)
|
0.572
|
|
Renal disease
|
65% (n = 109)
|
87% (n = 41)
|
0.003
|
|
Cancer
|
5% (n = 9)
|
11% (n = 5)
|
0.195
|
|
AIDS/HIV
|
0 (n = 0)
|
0 (n = 0)
|
n.s
|
|
Neurological disease
|
8% (n = 14)
|
6% (n = 3)
|
0.661
|
|
Lung disease
|
29% (n = 49)
|
40% (n = 19)
|
0.142
|
